REG - Fusion Antibodies - Launch of OptiMAL platform

Fusion AntibodiesAnnouncement

Tue 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251216:nRSP7820La&default-theme=true

RNS Number : 7820L  Fusion Antibodies PLC  16 December 2025

16 December 2025

 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Launch of the OptiMAL® Human Antibody Discovery platform

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, announces the official launch of the OptiMAL® platform for the
discovery of novel human antibodies. The OptiMAL® platform incorporates the
Company's naïve, synthetic library of antibody sequences and the Mammalian
Display used to select individual antibodies from the Library against a target
of interest. As has been previously announced by the Company, the OptiMAL®
library and the method for designing the Library are protected under US patent
no. US12378696 and patents pending in other territories.

 

The official launch of the OptiMAL® platform took place at the Antibody
Engineering and Therapeutics conference in San Diego with a speaker
presentation by Dr. Richard Buick, CSO, followed by poster presentations and
an exhibit booth. CEO Adrian Kinkaid also attended the official launch of
OptiMAL®.

 

Richard Buick, CSO of Fusion, said: "I am delighted to see the culmination of
several years' work presented to an audience of antibody industry peers and
look forward to the future of using this technology to bring more human
therapeutic antibodies to the market."

 

Enquiries:

 

 Investor questions on this announcement
 We encourage all investors to share questions on this announcement via our      Investor hub (https://investorhub.fusionantibodies.com/)
 investor hub

 Fusion Antibodies plc                                                           www.fusionantibodies.com
 Adrian Kinkaid, Chief Executive Officer                                         Via Walbrook PR

 Stephen Smyth, Chief Financial Officer

 Allenby Capital Limited                                                         Tel: +44 (0) 20 3328 5656
 James Reeve/Vivek Bhardwaj (Corporate Finance)

 Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

 Shard Capital Partners LLP
 Damon Heath (Joint Broker)                                                      Tel: +44 (0) 207 186 9952

 Walbrook PR                             Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
 Anna Dunphy                                                                     Mob: +44 (0)7876 741 001

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFEFFMEISESE



            Copyright 2019 Regulatory News Service, all rights reserved